Thursday, October 15, 2026

AI Credit Models Drive 7M Client Surge at Fintech Banks—But Delinquency Risk Looms

Digital banks using AI underwriting added millions of customers in 2025, with Inter & Co onboarding 7 million new clients and Nu Holdings deploying its nuFormer model across 100+ products. Regulatory shifts in Brazil slowed Nu's portfolio growth from 14% to 10%, while Inter projects private payroll loan delinquency above 10% in 2026, exposing model risk concentrated in algorithm-driven lending.

AI Credit Models Drive 7M Client Surge at Fintech Banks—But Delinquency Risk Looms
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Inter & Co welcomed 7 million new clients in 2025, its best annual performance, while Nu Holdings deployed its nuFormer AI credit model to production and launched more than 100 products and features. The customer acquisition surge marks a shift in emerging market lending, where digital banks using machine learning underwriting now outpace traditional competitors.

Nu's newer customer cohorts transact faster than older groups, a pattern Inter also reported. The acceleration reflects AI models identifying creditworthy borrowers traditional banks miss—or mispricing risk that surfaces later.

Brazil's November 2025 FGTS regulation changes triggered the first stress test. Nu's portfolio growth rate dropped from an expected 13-14% to roughly 10% as the AI model struggled to adapt to new lending constraints. The company typically sees 15-90 day NPLs tick up in Q1, indicating sensitivity to external shocks.

Inter expects its cost of risk in 2026 to reach 5.5-6%, with private payroll loan delinquency converging above 10%. The forecast suggests AI-driven growth creates concentrated exposure: models trained on stable periods may misread creditworthiness when macro conditions or regulations shift.

Traditional banks spread underwriting across human judgment and algorithmic inputs, diluting single-model failures. AI-native lenders face binary risk: their models either capture growth opportunities competitors miss or accumulate portfolios that deteriorate together under stress.

Nu's nuFormer deployment shows the upside—rapid feature rollout and customer scaling impossible with manual credit review. Inter's 7 million new clients demonstrate market demand for instant approvals. Both banks rely on algorithms to segment risk across millions of micro-decisions daily.

The delinquency projections reveal the downside. When external variables change—regulation, employment rates, government lending programs—AI models trained on historical patterns may continue approving profiles that no longer perform. Human underwriters adjust heuristics intuitively; algorithms require retraining cycles that lag market shifts.

Emerging market fintech growth now depends on model resilience, not just model accuracy. Banks that built portfolios in 2024-2025's favorable conditions will test whether their AI can navigate 2026's headwinds—or if speed-to-market came at the cost of durability.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com